Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.24

Margin Of Safety %

Put/Call OI Ratio

0.03

EPS Next Q Diff

EPS Last/This Y

2.05

EPS This/Next Y

0.56

Price

0.34

Target Price

16

Analyst Recom

1

Performance Q

29.67

Relative Volume

0.09

Beta

-0.48

Ticker: PRPH




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-04-14PRPH0.30560.037.503647
2025-04-15PRPH0.2910.037.503647
2025-04-16PRPH0.28730.030.003637
2025-04-17PRPH0.28690.031.003638
2025-04-18PRPH0.28810.031.003638
2025-04-21PRPH0.310.040.001943
2025-04-22PRPH0.350.040.001964
2025-04-23PRPH0.3460.040.001968
2025-04-24PRPH0.33350.04999.991969
2025-04-25PRPH0.36890.03575184016824401970
2025-04-28PRPH0.35030.03530633437175501994
2025-04-29PRPH0.34560.040.002009
2025-04-30PRPH0.33890.040.002009
2025-05-01PRPH0.32620.030.002086
2025-05-02PRPH0.33270.030.002086
2025-05-05PRPH0.29440.030.002086
2025-05-06PRPH0.26990.030.002089
2025-05-07PRPH0.2840.030.002090
2025-05-08PRPH0.30960.030.002090
2025-05-09PRPH0.30520.030.002092
2025-05-12PRPH0.32970.030.002214
2025-05-13PRPH0.33440.030.002215
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-04-14PRPH0.30-157.1- -0.56
2025-04-15PRPH0.29-157.1- -0.56
2025-04-16PRPH0.28-157.1- -0.56
2025-04-17PRPH0.29-157.1- -0.56
2025-04-18PRPH0.29-157.1- -0.56
2025-04-21PRPH0.31-157.1- -0.56
2025-04-22PRPH0.35-157.1- -0.56
2025-04-23PRPH0.35-157.1- -0.56
2025-04-24PRPH0.34-157.1- -0.56
2025-04-25PRPH0.37-157.1- -0.56
2025-04-28PRPH0.35-157.1- -0.56
2025-04-29PRPH0.34-157.1- -0.56
2025-04-30PRPH0.35-157.1- -0.56
2025-05-01PRPH0.32-157.1- -0.56
2025-05-02PRPH0.33-157.1- -0.56
2025-05-05PRPH0.29-157.1- -0.56
2025-05-06PRPH0.27-157.1- -0.56
2025-05-07PRPH0.29-157.1- -0.56
2025-05-08PRPH0.31-157.1- -0.56
2025-05-09PRPH0.30-157.1- -0.56
2025-05-12PRPH0.33-157.1- -0.56
2025-05-13PRPH0.34-157.1- -0.56
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-04-14PRPH0.0034.123.21
2025-04-15PRPH0.0034.123.21
2025-04-16PRPH0.0034.123.21
2025-04-17PRPH0.0034.123.21
2025-04-18PRPH0.0034.123.21
2025-04-21PRPH0.0033.923.21
2025-04-22PRPH0.0033.923.21
2025-04-23PRPH0.0033.923.21
2025-04-24PRPH0.0033.923.21
2025-04-25PRPH0.0033.923.21
2025-04-28PRPH0.0033.873.45
2025-04-29PRPH0.0033.873.45
2025-04-30PRPH0.0033.873.45
2025-05-01PRPH0.0033.873.45
2025-05-02PRPH0.0033.873.45
2025-05-05PRPH0.0022.443.45
2025-05-06PRPH0.0022.443.45
2025-05-07PRPH0.0022.443.45
2025-05-08PRPH0.0022.443.45
2025-05-09PRPH0.0022.443.45
2025-05-12PRPH0.0027.001.24
2025-05-13PRPH0.0027.001.24
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.15

Insider Transactions

Institutional Transactions

27

Beta

-0.48

Average Sales Estimate Current Quarter

5

Average Sales Estimate Next Quarter

3

Fair Value

Quality Score

14

Growth Score

33

Sentiment Score

86

Actual DrawDown %

97.9

Max Drawdown 5-Year %

-98.4

Target Price

16

P/E

Forward P/E

PEG

P/S

1.12

P/B

0.17

P/Free Cash Flow

EPS

-1.5

Average EPS Est. Cur. Y​

-0.56

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-217.64

Relative Volume

0.09

Return on Equity vs Sector %

-749.4

Return on Equity vs Industry %

-736.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.24

EBIT Estimation

ProPhase Labs, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 96
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today
news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance
stock history PRPH – ProPhase Labs Inc invest stock market
stock prices PRPH premarket after hours
ticker PRPH fair value insiders trading